We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection.
- Authors
Guimaraes, Alessander O; Cao, Yi; Hong, Kyu; Mayba, Oleg; Peck, Melicent C; Gutierrez, Johnny; Ruffin, Felicia; Carrasco-Triguero, Montserrat; Dinoso, Jason B; Clemenzi-Allen, Angelo; Koss, Catherine A; Maskarinec, Stacey A; Chambers, Henry F; Fowler, Vance G; Baruch, Amos; Rosenberger, Carrie M
- Abstract
Background Staphylococcus aureus is a leading cause of bacteremia, yet there remains a significant knowledge gap in the identification of relevant biomarkers that predict clinical outcomes. Heterogeneity in the host response to invasive S. aureus infection suggests that specific biomarker signatures could be utilized to differentiate patients prone to severe disease, thereby facilitating earlier implementation of more aggressive therapies. Methods To further elucidate the inflammatory correlates of poor clinical outcomes in patients with S. aureus bacteremia, we evaluated the association between a panel of blood proteins at initial presentation of bacteremia and disease severity outcomes using 2 cohorts of patients with S. aureus bacteremia (n = 32 and n = 124). Results We identified 13 candidate proteins that were correlated with mortality and persistent bacteremia. Prognostic modeling identified interleukin (IL)-8 and CCL2 as the strongest individual predictors of mortality, with the combination of these biomarkers classifying fatal outcome with 89% sensitivity and 77% specificity (P <.0001). Baseline IL-17A levels were elevated in patients with persistent bacteremia (P <.0001), endovascular (P =.026) and metastatic tissue infections (P =.012). Conclusions These results demonstrate the potential utility of selected biomarkers to distinguish patients with the highest risk for treatment failure and bacteremia-related complications, providing a valuable tool for clinicians in the management of S. aureus bacteremia. Additionally, these biomarkers could identify patients with the greatest potential to benefit from novel therapies in clinical trials.
- Subjects
BACTEREMIA; ENDOCARDITIS; BIOMARKERS; BLOODBORNE infections; INFLAMMATORY mediators; INTERLEUKINS; STAPHYLOCOCCUS aureus; TREATMENT effectiveness; SEVERITY of illness index; STATISTICAL models; HOSPITAL mortality; CATHETER-related infections; DISEASE complications; DISEASE risk factors
- Publication
Clinical Infectious Diseases, 2019, Vol 68, Issue 9, p1502
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciy739